Phase 2 Complete
NKTR-181 is a mu-opioid analgesic investigational drug candidate with a novel molecular structure designed to provide potent pain relief while reducing the serious side effects of respiratory depression, sedation and abuse potential associated with conventional opioids.
Pain is the most common symptom for which patients seek medical attention.1 According to the American Pain Society, the prevalence of chronic pain in the United States is estimated to be 35.5% or 105 million people. Chronic pain costs more than $100 billion per year in direct health-care expenditures and lost work time. Opioids are considered to be the most effective therapeutic option for pain and have over $10 billion a year in sales in the U.S. alone.2,3 However, opioids cause significant problems for physicians and patients because of their serious side effects such as respiratory depression and sedation, as well as the risks they pose for addiction, abuse, misuse, and diversion. The U.S. Food and Drug Administration has cited prescription opioid analgesics as being at the center of a major public health crisis of addiction, misuse, abuse, overdose and death.4 A 2010 report from the Centers for Disease Control (CDC) notes that emergency room visits tied to the abuse of prescription painkillers is at an all-time high, having increased 111 percent over a five-year period.5
NKTR-181 was uniquely designed to cross the blood-brain barrier at a substantially slower rate than other opioid therapies. With a reduced rate of entry into the CNS, NKTR-181 has the potential to eliminate not only the euphoria that underlies opioid abuse liability and dependence but also the serious CNS-related side effects of respiratory depression and sedation. The unique molecular design of the polymer drug conjugate also prevents conversion of NKTR-181 into a rapid-acting abusable form of an opioid. As a result, NKTR-181 has the potential to be a highly effective analgesic with a highly favorable safety profile and reduced abuse potential.
NKTR-181 has completed Phase 2 development and is being prepared for Phase 3 clinical studies.
|September 3-6, 2014
||Las Vegas, NV|
|September 18-21, 2014
||American Academy of Pain Mgmt Annual Meeting
|October 6-11, 2014
||IASP 15th World Congress on Pain
||Buenos Aires, Argentina|
|November 5-6, 2014
||7th Annual Pain & Migraine Therapeutics Summit West
||San Francisco, CA|
|November 15-19, 2014
||Society for Neuroscience: Neuroscience 2014
|| Washington, DC|
View our Scientific & Medical event calendar »